Design, Synthesis, and Evaluation of Novel (−) ‐cis‐N‐ Normetazocine Derivatives: In Vitro and Molecular Modeling Insights
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Giuliana Costanzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug and Health Sciences, University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Drug Design, Receptors, Opioid, kappa, Receptors, Opioid, mu, Cyclazocine. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Catania, PIA.CE.RI. 2020-2022 Linea di intervento 2, project DETTAGLI (grant 57722172125), Università di Catania.
Abstract (Originalsprache)
Suitable structural modifications of the functional groups at N ‐substituent of (−)‐ cis ‐ N ‐normetazocine nucleus modulate the affinity and activity profile of related ligands toward opioid receptors. Our research group has developed several compounds and the most interesting ligands, LP1 and LP2 , exhibited a dual‐target profile for mu‐opioid receptor (MOR) and delta‐opioid receptor (DOR). Recent structure–affinity relationship studies led to the discovery of novel LP2 analogs (compounds 1 and 2 ), which demonstrated high MOR affinity in the nanomolar range. Here, we reported the synthesis of the new (−)‐ cis ‐ N ‐normetazocine derivatives ( 3 – 8 ) characterized by the absence of the phenyl ring in the N ‐substituent compared to all previous reported ligands. Compounds 3 and 4 , featuring a methyl ester functional group in the N ‐substituent, retained significant MOR affinity and exhibited similar affinity for the kappa‐opioid receptor (KOR). In contrast, compounds 7 and 8 , which contain a hydroxamic acid functionality, maintained affinity exclusively toward MOR. Neither of compounds ( 3 – 8 ) showed DOR affinity. Molecular modeling studies confirmed a similar docking pose in the MOR binding pocket for these compounds. Additionally, the in silico ADME profile of the most interesting ligands ( 3 , 4 , 7 , and 8 ) was investigated revealing a favorable profile for compound 7 regarding the blood–brain barrier permeability, suggesting its potential as a peripherally restricted opioid ligand.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug and Health Sciences, University of Catania, Catania, Italy.
ORCID-Profile: Giuliana Costanzo, Alessandro Coco, Giuseppe Cosentino, Vincenzo Patamia, Carmela Parenti, Emanuele Amata, Agostino Marrazzo, Antonio Rescifina, Lorella Pasquinucci
Förderung
- University of Catania, PIA.CE.RI. 2020-2022 Linea di intervento 2, project DETTAGLI (grant 57722172125)
- Università di Catania
Zitieren
APA
Costanzo, G., Coco, A., Cosentino, G., Patamia, V., Parenti, C., Amata, E., Marrazzo, A., Rescifina, A., & Pasquinucci, L. (2024). Design, Synthesis, and Evaluation of Novel (−) ‐cis‐N‐ Normetazocine Derivatives: In Vitro and Molecular Modeling Insights. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70037
Vancouver
Costanzo G, Coco A, Cosentino G, Patamia V, Parenti C, Amata E, et al. Design, Synthesis, and Evaluation of Novel (−) ‐cis‐N‐ Normetazocine Derivatives: In Vitro and Molecular Modeling Insights. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70037
BibTeX
@article{Costanzo2024,
author = {Costanzo, Giuliana and Coco, Alessandro and Cosentino, Giuseppe and Patamia, Vincenzo and Parenti, Carmela and Amata, Emanuele and Marrazzo, Agostino and Rescifina, Antonio and Pasquinucci, Lorella},
title = {Design, Synthesis, and Evaluation of Novel (−) ‐cis‐N‐ Normetazocine Derivatives: In Vitro and Molecular Modeling Insights},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.70037}
}
EUVIMED